Barclays
NVCR icon

Barclays’s NovoCure NVCR Stock Holding History

Barclays’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Sell
297,416
-149,839
-34% -$1.87M ﹤0.01% 2078
2025
Q4 		$5.78M Buy
447,255
+49,233
+12% +$632K ﹤0.01% 2109
2025
Q3 		$5.14M Sell
398,022
-16,269
-4% -$217K ﹤0.01% 2175
2025
Q2 		$7.37M Buy
414,291
+134,379
+48% +$2.34M ﹤0.01% 1792
2025
Q1 		$4.99M Sell
279,912
-180,143
-39% -$4.09M ﹤0.01% 1916
2024
Q4 		$13.7M Buy
460,055
+6,350
+1% +$134K ﹤0.01% 1338
2024
Q3 		$7.09M Buy
453,705
+131,389
+41% +$2.38M ﹤0.01% 1753
2024
Q2 		$5.52M Buy
322,316
+86,916
+37% +$1.53M ﹤0.01% 1478
2024
Q1 		$3.68M Buy
235,400
+129,866
+123% +$1.91M ﹤0.01% 2062
2023
Q4 		$1.58M Buy
105,534
+59,754
+131% +$800K ﹤0.01% 3106
2023
Q3 		$739K Sell
45,780
-36,772
-45% -$1.06M ﹤0.01% 2550
2023
Q2 		$3.43M Sell
82,552
-9,970
-11% -$619K ﹤0.01% 1577
2023
Q1 		$5.56M Buy
92,522
+14,636
+19% +$1.17M ﹤0.01% 1470
2022
Q4 		$5.71M Buy
77,886
+1,975
+3% +$149K ﹤0.01% 1523
2022
Q3 		$5.77M Buy
75,911
+5,259
+7% +$410K 0.01% 1079
2022
Q2 		$4.91M Buy
70,652
+13,161
+23% +$991K ﹤0.01% 1354
2022
Q1 		$4.76M Sell
57,491
-10,131
-15% -$746K ﹤0.01% 1276
2021
Q4 		$5.08M Sell
67,622
-4,718
-7% -$474K ﹤0.01% 1701
2021
Q3 		$8.4M Sell
72,340
-9,864
-12% -$1.49M ﹤0.01% 1293
2021
Q2 		$18.2M Buy
82,204
+19,200
+30% +$3.73M 0.01% 931
2021
Q1 		$8.33M Buy
63,004
+22,646
+56% +$3.58M ﹤0.01% 1169
2020
Q4 		$6.98M Buy
40,358
+28,552
+242% +$3.91M ﹤0.01% 1333
2020
Q3 		$1.31M Sell
11,806
-301,409
-96% -$24.1M ﹤0.01% 2452
2020
Q2 		$18.6M Sell
313,215
-104,129
-25% -$6.85M 0.01% 675
2020
Q1 		$28.1M Sell
417,344
-83,352
-17% -$6.59M 0.02% 505
2019
Q4 		$42.2M Buy
500,696
+53,527
+12% +$4.32M 0.02% 579
2019
Q3 		$33.4M Buy
447,169
+120,168
+37% +$9.61M 0.02% 620
2019
Q2 		$20.7M Buy
327,001
+16,485
+5% +$835K 0.01% 910
2019
Q1 		$15M Buy
310,516
+309,711
+38,473% +$14.9M 0.01% 1004
2018
Q4 		$27K Sell
805
-28,090
-97% -$1.03M ﹤0.01% 5772
2018
Q3 		$1.51M Buy
28,895
+20,189
+232% +$804K ﹤0.01% 3218
2018
Q2 		$272K Sell
8,706
-8,307
-49% -$231K ﹤0.01% 4464
2018
Q1 		$371K Sell
17,013
-7,827
-32% -$168K ﹤0.01% 4258
2017
Q4 		$502K Buy
24,840
+13,512
+119% +$260K ﹤0.01% 3829
2017
Q3 		$226K Buy
11,328
+5,787
+104% +$114K ﹤0.01% 4318
2017
Q2 		$96K Sell
5,541
-442
-7% -$5.71K ﹤0.01% 4938
2017
Q1 		$48K Sell
5,983
-55,596
-90% -$401K ﹤0.01% 5358
2016
Q4 		$484K Buy
61,579
+60,396
+5,105% +$486K ﹤0.01% 3401
2016
Q3 		$10K Buy
1,183
+1,083
+1,083% +$9.88K ﹤0.01% 5798
2016
Q2 		$1K Sell
100
-26,772
-100% -$335K ﹤0.01% 6133
2016
Q1 		$376K Buy
26,872
+26,688
+14,504% +$383K ﹤0.01% 3359
2015
Q4 		$4K Buy
+184
New +$4.39K ﹤0.01% 5619

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Barclays's NVCR Position: Q1 2026 in Review

Barclays reduced its NovoCure (NVCR) stake by 34% in Q1 2026, selling an estimated $1.87M and leaving 297,416 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Barclays first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $42.2M in Q4 2019. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Barclays held 297,416 shares of NovoCure worth $3.24M as of Q1 2026.
  • Barclays sold 149,839 NovoCure shares in Q1 2026, an estimated $1.87M.
  • NovoCure made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2078 holding.
  • Barclays first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
  • Barclays's NovoCure position peaked at $42.2M in Q4 2019.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.